Join

Compare · BDSX vs ILMN

BDSX vs ILMN

Side-by-side comparison of Biodesix Inc. (BDSX) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BDSX and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
  • ILMN is the larger of the two at $25.86B, about 155.1x BDSX ($166.7M).
  • Over the past year, BDSX is up 166.8% and ILMN is up 109.1% - BDSX leads by 57.7 points.
  • ILMN has been more active in the news (24 items in the past 4 weeks vs 6 for BDSX).
  • ILMN has more recent analyst coverage (25 ratings vs 7 for BDSX).
PerformanceBDSX+166.83%ILMN+109.10%
2025-06-03+0.00%2026-06-03
MetricBDSXILMN
Company
Biodesix Inc.
Illumina Inc.
Price
$16.01+4.71%
$171.04+5.25%
Market cap
$166.7M
$25.86B
1M return
+38.14%
+22.71%
1Y return
+166.83%
+109.10%
Industry
Medical Specialities
Medical Specialities
Exchange
NASDAQ
NASDAQ
IPO
2020
2000
News (4w)
6
24
Recent ratings
7
25
BDSX

Biodesix Inc.

Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions. It also provides Bio-Rad SARS-CoV-2 ddPCR test, which is designed to detect the presence of infection by the SARS-CoV-2 virus; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. In addition, the company offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.

ILMN

Illumina Inc.

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.

Latest BDSX

Latest ILMN